CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $36,996,096
- in 12 filings, $37.0M under 10b5-1 plans
Net −$36,996,096. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Telman Deborah H EVP, Corporate Affairs & GC | Grant or award · Restricted Stock Unit | +7,680 | 32,216 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +4,916 | $63.91 | $314K | 173,977 |
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +13,013 | $63.91 | $832K | 186,990 |
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −4,916 | $117.30 | $577K | 182,074 |
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −13,013 | $118.50 | $1.5M | 169,061 |
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +7,968 | 177,029 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Shares withheld for taxes 10b5-1 | −3,855 | $117.21 | $452K | 173,174 |
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −4,916 | 13,013 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −13,013 | 0 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise · Restricted Stock Unit 10b5-1 | −7,968 | 27,519 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Grant or award · Non-qualified Stock Option (Right to Buy) 10b5-1 | +49,020 | 49,020 | ||
| 2025-03-10 | Dickinson Andrew D Chief Financial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +11,090 | 38,609 | ||
| 2025-03-10 | Patterson Sandra SVP, Controllership | Option exercise | +1,952 | 40,077 | ||
| 2025-03-10 | Patterson Sandra SVP, Controllership | Shares withheld for taxes | −624 | $117.21 | $73K | 39,453 |
| 2025-03-10 | Patterson Sandra SVP, Controllership | Option exercise · Restricted Stock Unit | −1,952 | 9,875 | ||
| 2025-03-10 | Berger Dietmar Chief Medical Officer | Grant or award · Restricted Stock Unit | +8,530 | 57,505 | ||
| 2025-03-10 | Berger Dietmar Chief Medical Officer | Grant or award · Non-qualified Stock Option (Right to Buy) | +37,710 | 37,710 | ||
| 2025-02-18 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −2,500 | $104.09 | $260K | 169,061 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +77,691 | $63.91 | $5.0M | 248,914 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +26,175 | $57.92 | $1.5M | 275,089 |
Page 19 of 30 · 599 trades